Joanna Kubar

Joanna Kubar

Auto-generated profile, based on publicly available information

Joanna Kubar

EA2675 (GRIPL), Faculté de Médecine, Nice, France.<>

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1999 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
YFYves le Fichoux
Yves le Fichoux
JQJean-FrançoIs Quaranta
Jean-FrançoIs Quaranta
JAJean-Pierre Aufeuvre
Jean-Pierre Aufeuvre
ALAlain Lelievre
Alain Lelievre
PMPierre Marty
Pierre Marty
JKJoanna Kubar
Joanna Kubar
Visceral leishmaniosis (VL) due toLeishmania infantum(L. chagasi) is a lethal disease if untreated, but asymptomaticL. infantuminfections have been reported previously. A better understanding of parasite transmission, dissemination, and survival in the human host is needed. The purpose of this study was to assess whetherL. infantumcirculated in peripheral blood of subjects with no history of VL. Sera from 565 blood donors were screened by Western blotting to detectLeishmania-specific antibodies and identify individuals with probable past exposure toLeishmania. Seropositivity was found in 76 donors whose buffy coats were examined by PCR and direct culture. The parasite minicircle kinetoplast DNA was amplified from blood samples of nine donors. Promastigotes were detected by culture in blood samples from nine donors. Only two donors were PCR and culture positive. These results indicate thatL. infantumcirculates intermittently and at low density in the blood of healthy seropositive individuals, who thus appear to be asymptomatic carriers. Implications for the safety of blood transfusion are discussed.

12 November 1998 in AIDS
Verified
Journal Article
Closed access
JKJoanna Kubar
Joanna Kubar
PMPierre Marty
Pierre Marty
ALAlain Lelièvre
Alain Lelièvre
JQJean-François Quaranta
Jean-François Quaranta
PSPascal Staccini
Pascal Staccini
YFYves Le Fichoux
Yves Le Fichoux
Objective: To discriminate cases of visceral leishmaniosis (VL) following a primary infection from cases originating in a reactivation of a latent Leishmania infection and to assess the impact of CD4+ T-cell counts on the occurrence of VL in patients with HIV disease. Methods: We searched by Western blotting for the presence of Leishmania infantum-specific antibodies in the sera of 236 HIV-positive patients. We performed a follow-up of antileishmanial serology and analysed the evolution of the CD4+ T-cell counts for 14 HIV-positive VL patients and for 18 HIV-positive Leishmania-seropositive patients without VL. Results: This study (1) showed that the VL disease/Leishmania infection ratio in HIV-positive individuals is high (1 : 10); (2) discriminated between a primary Leishmania infection (five patients who converted from Leishmania-seronegative to Leishmania-seropositive) and a reactivation of a latent infection (seven patients); (3) showed that HIV-positive individuals with dramatically low CD4+ T-cell counts maintained or generated a specific antileishmanial antibody production; (4) demonstrated that the primary-VL appeared at significantly higher (P = 0.028) CD4+ T-cell levels than the reactivation-VL; (5) documented the existence of HIV-positive Leishmania-seropositive individuals who despite a severe and prolonged immunosuppression did not develop VL (eight of 18). Conclusion: Our data stress the utility of the follow-up by Western blotting for an early diagnosis of VL, and therefore an early treatment, for HIV-positive patients living in endemic areas. They suggest that in a latent Leishmania infection supplementary control mechanism(s) might operate in addition to the T-cell-mediated response, and provide a further example of non-appearance of an opportunistic infection despite a severe reduction in CD4+ T cells.

17 August 2001 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
DRDéborah Rousseau
Déborah Rousseau
SDSylvie Demartino
Sylvie Demartino
BFBernard Ferrua
Bernard Ferrua
JMJean-Francois MICHIELS
Jean-Francois MICHIELS
FAFabienne Anjuère
Fabienne Anjuère
JKJoanna Kubar
Joanna Kubar
The role of lymphocytes in the specific defence against L. infantum has been well established, but the part played by polynuclear neutrophil (PN) cells in controlling visceral leishmaniasis was much less studied. In this report we examine in vivo the participation of PN in early and late phases of infection by L. infantum. Promastigote phagocytosis and killing occurs very early after infection, as demonstrated by electron microscopy analyses which show in BALB/c mouse spleen, but not in liver, numerous PN harbouring ultrastructurally degraded parasites. It is shown, using mAb RB6-8C5 directed against mature mouse granulocytes, that in chronically infected mice, long-term PN depletion did not enhance parasite counts neither in liver nor in spleen, indicating that these cells are not involved in the late phase of L. infantum infection. In acute stage of infection, in mouse liver, where L. infantum load is initially larger than that in spleen but resolves spontaneously, there was no significant effect of neutrophils depletion. By contrast, early in infection the neutrophil cells crucially contributed to parasite killing in spleen, since PN depletion, performed before and up to 7 days after the parasite inoculation, resulted in a ten-fold increase of parasite burden. Taken together these data show that neutrophil cells contribute to the early control of the parasite growth in spleen but not in liver and that these cells have no significant effect late in infection in either of these target organs.

1 March 1998 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
YFYves Le Fichoux
Yves Le Fichoux
DRDébOrah Rousseau
DébOrah Rousseau
BFBernard Ferrua
Bernard Ferrua
SRSandrine Ruette
Sandrine Ruette
ALAlain LelièvRe
Alain LelièvRe
JKJoanna Kubar
Joanna Kubar
In the immunocompetent host, visceral leishmaniasis (VL) is a fatal disease if untreated. In immunosuppressed patients, VL is an opportunistic infection for which there is no effective treatment for relapses. Here we report on the long-term activity of orally administered hexadecylphosphocholine (HDPC) against establishedLeishmania infantuminfection in BALB/c mice. HDPC is a synthetic phospholipid with antiproliferative properties that has been extensively studied for its cancerostatic activity. Its short-term leishmanicidal effects in mice recently infected with viscerotropicLeishmaniaspecies have been previously reported. First, we show that 5 days of oral therapy with HDPC (20 mg/kg of body weight/day) led to amastigote suppression in the liver and the spleen of 94 and 78%, respectively (versus 85 and 55% suppression by meglumine antimonate in the liver and spleen, respectively), in mice infected 6 weeks before treatment and examined 3 days after the end of treatment. These results demonstrate the short-term efficacy of HDPC against an establishedLeishmaniainfection. Next, the long-term efficacy of HDPC was examined. In HDPC-treated mice both the hepatic and splenic amastigote loads were significantly reduced (at least 89%) 10, 31, and 52 days after the end of the treatment. In the treated mice, the increase of the splenic load was significantly slower than that in the untreated mice, demonstrating that the HDPC-exerted inhibition ofLeishmaniagrowth persisted for at least 7 to 8 weeks. Orally administered HDPC—the safe doses and side effects of which are at least partially known—appears to be a promising candidate for the treatment of VL.

1 February 2005 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JKJoanna Kubar
Joanna Kubar
KFKonstantina Fragaki
Konstantina Fragaki

1 February 2000 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
ISIsabelle Suffia
Isabelle Suffia
BFBernard Ferrua
Bernard Ferrua
XSXavier Stien
Xavier Stien
BMBaharia Mograbi
Baharia Mograbi
PMPierre Marty
Pierre Marty
JKJoanna Kubar
Joanna Kubar
We report here the characterization of a novelLeishmania infantumprotein termed papLe22 (22-kDa potentially aggravating protein ofLeishmania). A positive clone from a cDNA library was identified by serum of a visceral leishmaniasis (VL) patient. Full-length cDNA obtained using rapid amplification of cDNA ends-PCR codes for a 22-kDa protein. InL. infantumpromastigotes an endogenous nuclear protein of 14-kDa electrophoretic mobility was found by using an antiserum prepared against the fusion protein glutathioneS-transferase–papLe22. Its expression was also shown inL. infantumamastigotes and inLeishmania majorandLeishmania guyanensispromastigotes. VL patients' sera showed anti-papLe22 immunoglobulin M (IgM) and IgG reactivities, indicating that a primary response against the leishmanial protein papLe22 accompanied acute VL manifestations. Specific IgG levels were correlated with patients' clinical status. The presence of IgG1, IgG2, and IgG3 subclasses suggested a mixed Th1- and Th2-type response; there was no correlation between subclass reactivity and the disease course. The recombinant papLe22 specifically activated interleukin-10 production by VL patients' peripheral blood mononuclear cells collected at diagnosis and after treatment-induced cure, indicating its contribution to VL pathogenesis and concomitant immunosuppression and its potential role in the reactivation of latent parasites. As a dominant immunogen, papLe22 might be used as a vaccine component, provided that the vaccination protocol directs the response toward the Th1 pattern.